Thanks to all participants for a fantastic meeting with focus on all aspects of #mycobacteriology at #ESMyco2025

Great presentation from Xenia at #esm2025 supported by @micronorman.bsky.social and @tlillebaek.bsky.social and others on decades of NTM isolates from patients and how it changes over those years.

A huge congratulations to
@jodyphelan.bsky.social from @lshtm.bsky.social l for receiving the Gertrud Meissner Award at #ESM2025! 🏆 His work on bioinformatic pipelines to predict drug resistance is truly impactful. Well deserved! 🎉 #Tuberculosis #Awards #Science

The prestigious Gardner Middlebrook Award is presented to Brigitte Gicquel from @pasteur.fr at #ESM2025. 🏆 Congratulations on this incredible honor, recognizing your immense contributions to our understanding of TB genetics and virulence. 👏 #Mycobacteriology

How to #treat #TB patients with #expanded #resistance to one or more of bedaquiline, linezolid, a third-generation fluoroquinolone, a nitroimidazole (pretomanid or delamanid, and/or clofazimine? Clinical experts elaborates best clinical practices, read on:

pmc.ncbi.nlm.nih.gov/articles/PMC...

It´s onsite, 09 - 11 September 2025
Vilnius, Lithuania.

Program www.escmid-foundation.org/fileadmin/es...

Join course "Optimising Management of TB and Mycobacterial Infections with Genomic Approaches". For mycobacteriology experts and young clinicians. Ideally, candidate trainees should be involved in implementation of NGS technologies for clinical management of TB & other mycobacterial diseases / NTM

New review study from colleagues, On the way to #tuberculosis #elimination, expanded #contact #tracing including additional subgroups may play a role. Perhaps first, let us make sure contact tracing is performed systematically in already recommended groups/populations? doi.org/10.5588/pha....

Last chance to submit your abstract Monday. Join us at European Society of Mycobacteriology annual congress in Lisbon, Portugal 🔬 #ESMyco

Also in DK, we need strong support networks and health systems that reach the vulnerable groups where they are. Let’s not wait for the numbers to rise like in UK but but focus on targeted prevention to stay ahead of the curve.

TB continues to disproportionately affect the most vulnerable. E.g. people experiencing homelessness, migration and socio-economic instability. They are at higher risk of infection and face barriers that complicate access to diagnosis and completion of treatment.

The BMJ editorial underscores the need for pronged action, stronger healthcare support, and targeted interventions, especially for vulnerable groups.
In Denmark, we don´t see the same general increase in TB incidence. However, we see similar patterns within specific high-risk groups

Things can change fast. In UK, after > a decade of declining incidence, TB is once again on the rise. In 2024, 5,480 people fell ill with TB in England, an increase of 13% from 2023, marking the highest rise since 1970 and continuing a worrying trend from 2021​.

Facts and myths about measles - The Lancet Infectious Diseases www.thelancet.com/journals/lan...

It's World Tuberculosis Day,let's unite to stop TB in its tracks! 🚫🦠 Join us at the vibrant 45th Annual Congress of the European Society of Mycobacteriology in Lisbon (22-25 June 2025). Save the date, register today! 🎯 www.esmycobacteriology.eu/event-home #EndTB

Venn diagram of the fulfilment of diagnostic guideline criteria for NTM pulmonary disease (n=184, 9 patients did not fulfil any component of the criteria)

N=193. MAC (56%), gordonae (15%), xenopi (11%) most common. Cough (62%), expectoration (51%), dyspnea (43%), and systemic symp. (42%), with 36% symptoms for > 6 mths. Median time first hospital contact to first NTM sample 14 days. 45% ptt. seen in a fast-track pulmonary cancer referral pathway.

New nationwide study investigating clinical characteristics and diagnostic practices in patients with pulmonary nontuberculous (NTM) isolates.

Happening a week today! If attending in person, please register ASAP - tickets are going fast!

Yes, but they often include B, L (or D also difficult to get). I understood your initial question/comment as what to do if BPaL not available.
BW

Pretomanid is a key anti-TB drug. Current EMA-approved label restricts its use to the BPaL regimen & only MDR/XDR-TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This implies using older regimens. In this Editorial, we call for label expansion:

I am not involved in the study but just found it interesting. Do you mean what should be used if you don´t have access to BPaL but do have fluoroquinolones? That would indeed be a longer (difficult) individualized regimen